Denmark reassesses rejection of Novartis cancer combination to include more exceptions

The Danish Medicines Council has re-evaluated a combination treatment application from Novartis that it rejected in 2018. The answer is still no, but there are now more exceptions attached.

Photo: Arnd Wiegmann/Reuters/Ritzau Scanpix

Members of the Danish Medicines Council have said no to an application from Novartis, which was hoping to see drugs Tafinlar (dabrafenib) and Mekinist (trametinib) approved as a as standard combination treatment for stage III melanoma with the BRAF V600 mutation, the council reports on its website.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs